Article

Difluprednate improves results after cataract surgery

Pre- and postoperative treatment with the potent corticosteroid difluprednate ophthalmic solution 0.05% significantly improves outcomes after cataract surgery compared with use of prednisolone acetate ophthalmic suspension 1% and so results in patient satisfaction.

Dr. Donnenfeld presented the results from a prospective, multicenter, observer-masked study he conducted with Edward Holland, MD, and Kerry Solomon, MD. The trial randomly assigned 39 patients undergoing bilateral cataract surgery to use of difluprednate in one eye and prednisolone acetate contralaterally.

The second eye was operated on after a 2-week interval, and all surgeries were uncomplicated. The corticosteroids were administered in a pulsed regimen perioperatively (10 doses) and then with a 2-week tapering course postoperatively.

"Despite advances in cataract surgery technique and technology, we have been disappointed that many patients still have cloudy corneas or even mild corneal thickening postoperatively that decreases their quality of vision," said Dr. Donnenfeld, founding partner, Ophthalmic Consultants of Long Island and Connecticut, and clinical professor of ophthalmology, New York University, New York. "Results of our controlled study document that use of difluprednate addresses this issue and improves the postoperative results in statistically and clinically significant ways.

"I have been using difluprednate in all of my cataract surgery patients for [more than] a year," he added. "My patients are much happier because of the 'wow' effect on their vision and are more likely to spread the word to everyone they know about their positive experience."

Several lines of evidence led Dr. Donnenfeld and colleagues to consider the pulsed difluprednate regimen as a solution to achieving improved outcomes after cataract surgery. Recognizing that high-dose corticosteroids are used in neurology and neurosurgery to reduce post-traumatic neuronal degeneration, improve neuronal function, and prevent neuronal cell death after spinal cord injury, they reasoned that because the corneal endothelium is also of neuroectodermal origin, a similar regimen might be beneficial for corneal protection in cataract surgery.

"I have found difluprednate to be the steroid of choice for all complicated cataract [procedures]," said Dr. Holland, director of cornea services, Cincinnati Eye Institute, and professor of ophthalmology, University of Cincinnati. "These include cases involving iris manipulation with hooks or rings, prolonged phaco time due to a dense cataract, capsule fixation or IOL suturing, and capsule tear or vitreous loss."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.